NIH Cuts Funding for Studies on Vaccine Hesitancy and Acceptance

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on March 11, 2025.

By I. Edwards HealthDay Reporter

TUESDAY, March 11, 2025 -- The National Institutes of Health (NIH) is cutting or canceling more than 40 grants focused on vaccine hesitancy and ways to increase vaccine acceptance, according to an email obtained by The Washington Post.

The message — sent Monday by Michelle Bulls, director of the Office of Policy for Extramural Research Administration — directed staff to terminate funding immediately. It said the research no longer aligns with agency priorities, according to The Post.

The email spelled out specific language to be used in the termination notice: “It is the policy of NIH not to prioritize research activities that focuses gaining scientific knowledge on why individuals are hesitant to be vaccinated and/or explore ways to improve vaccine interest and commitment. … Therefore, the award is terminated.”

The move dovetails with new leadership at the U.S. Department of Health and Human Services (HHS). New HHS Secretary Robert F. Kennedy Jr. has long questioned vaccine safety and has promoted scientifically debunked claims linking vaccines to autism.

It's unclear if Kennedy played a direct role in the decision, but his appointment has unsettled the medical research community.

Experts warn the funding cuts come at a critical time. The U.S. has reported 222 measles cases across 12 states this year, with vaccination rates among kindergartners declining since 2019. One child has died from measles and another death is under investigation, according to the U.S. Centers for Disease Control and Prevention (CDC).

Researcher Manoj Sharma had a CDC grant that ended last year to evaluate vaccine hesitancy and told The Post that the current outbreak underscores the importance of continued research.

“There is an urgent need to enhance vaccine acceptance behavior, especially due to the potential resurgence of measles and COVID-19 still looming,” said Sharma, a professor of social and behavioral health at the University of Nevada at Las Vegas.

Delesha Carpenter, a researcher at the University of North Carolina at Chapel Hill, has spent three years studying COVID vaccine hesitancy through a previous NIH grant.

She fears the termination of research will limit efforts to provide the public with reliable vaccine information.

“If we take away research on vaccine hesitancy, we’re also going to be taking away the ability to provide people with the best information about whether the vaccine is in their best interest,” Carpenter said. “They still have the decision to make.”

The NIH is also reducing funding for research on transgender issues, diversity and inclusion and Chinese universities.

The Post reported that internal documents showed that last week, grants management staffers received guidance on how to terminate funding in these areas.

Sources

  • The Washington Post, March 10, 2025

    • Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

    Source: HealthDay

    Posted : 2025-03-12 00:00

    Read more

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords